A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) often accompanies lung cancer, and life-threatening acute exacerbation (AE) of IPF (AE-IPF) is reported to occur in 20 % of IPF patients who undergo lung cancer surgery. Pirfenidone is an anti-fibrotic agent known to reduce disease progression in IPF p...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Takekazu, Yoshino, Ichiro, Yoshida, Shigetoshi, Ikeda, Norihiko, Tsuboi, Masahiro, Asato, Yuji, Katakami, Nobuyuki, Sakamoto, Kazuhiro, Yamashita, Yoshinori, Okami, Jiro, Mitsudomi, Tetsuya, Yamashita, Motohiro, Yokouchi, Hiroshi, Okubo, Kenichi, Okada, Morihito, Takenoyama, Mitsuhiro, Chida, Masayuki, Tomii, Keisuke, Matsuura, Motoki, Azuma, Arata, Iwasawa, Tae, Kuwano, Kazuyoshi, Sakai, Shuji, Hiroshima, Kenzo, Fukuoka, Junya, Yoshimura, Kenichi, Tada, Hirohito, Nakagawa, Kazuhiko, Nakanishi, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957367/
https://www.ncbi.nlm.nih.gov/pubmed/27450274
http://dx.doi.org/10.1186/s12931-016-0398-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957367/
https://www.ncbi.nlm.nih.gov/pubmed/27450274
http://dx.doi.org/10.1186/s12931-016-0398-4

Ejemplares similares